OTLK Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of -1338.77% compared to Outlook Therapeutics, Inc.'s net margin of 10.24%. Outlook Therapeutics, Inc.'s return on equity of -- beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Outlook Therapeutics, Inc. has a consensus price target of $6.83, signalling upside risk potential of 1151.07%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 3.51%. Given that Outlook Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Outlook Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..

Outlook Therapeutics, Inc. has a beta of 0.174, which suggesting that the stock is 82.557% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.

Outlook Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Outlook Therapeutics, Inc. quarterly revenues are $1.5M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Outlook Therapeutics, Inc.'s net income of -$20.2M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Outlook Therapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics, Inc. is 10.52x versus 7.33x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ironwood Pharmaceuticals, Inc. has a net margin of -1338.77% compared to Outlook Therapeutics, Inc.'s net margin of 32.84%. Outlook Therapeutics, Inc.'s return on equity of -- beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.

Outlook Therapeutics, Inc. has a consensus price target of $6.83, signalling upside risk potential of 1151.07%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $3.17 which suggests that it could fall by -29.63%. Given that Outlook Therapeutics, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Outlook Therapeutics, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Outlook Therapeutics, Inc. has a beta of 0.174, which suggesting that the stock is 82.557% less volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.185, suggesting its less volatile than the S&P 500 by 81.483%.

Outlook Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics, Inc. pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Outlook Therapeutics, Inc. quarterly revenues are $1.5M, which are smaller than Ironwood Pharmaceuticals, Inc. quarterly revenues of $122.1M. Outlook Therapeutics, Inc.'s net income of -$20.2M is lower than Ironwood Pharmaceuticals, Inc.'s net income of $40.1M. Notably, Outlook Therapeutics, Inc.'s price-to-earnings ratio is -- while Ironwood Pharmaceuticals, Inc.'s PE ratio is 29.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics, Inc. is 10.52x versus 2.24x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -1338.77% compared to Outlook Therapeutics, Inc.'s net margin of -255.85%. Outlook Therapeutics, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Outlook Therapeutics, Inc. has a consensus price target of $6.83, signalling upside risk potential of 1151.07%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -94.25%. Given that Outlook Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Outlook Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Outlook Therapeutics, Inc. has a beta of 0.174, which suggesting that the stock is 82.557% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Outlook Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Outlook Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Outlook Therapeutics, Inc. quarterly revenues are $1.5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Outlook Therapeutics, Inc.'s net income of -$20.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Outlook Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 24.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics, Inc. is 10.52x versus 28.70x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Neogen Corp. has a net margin of -1338.77% compared to Outlook Therapeutics, Inc.'s net margin of -7.09%. Outlook Therapeutics, Inc.'s return on equity of -- beat Neogen Corp.'s return on equity of -25.93%.

Outlook Therapeutics, Inc. has a consensus price target of $6.83, signalling upside risk potential of 1151.07%. On the other hand Neogen Corp. has an analysts' consensus of $11.67 which suggests that it could grow by 26.13%. Given that Outlook Therapeutics, Inc. has higher upside potential than Neogen Corp., analysts believe Outlook Therapeutics, Inc. is more attractive than Neogen Corp..

Outlook Therapeutics, Inc. has a beta of 0.174, which suggesting that the stock is 82.557% less volatile than S&P 500. In comparison Neogen Corp. has a beta of 1.956, suggesting its more volatile than the S&P 500 by 95.564%.

Outlook Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neogen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics, Inc. pays -- of its earnings as a dividend. Neogen Corp. pays out -- of its earnings as a dividend.

Outlook Therapeutics, Inc. quarterly revenues are $1.5M, which are smaller than Neogen Corp. quarterly revenues of $224.7M. Outlook Therapeutics, Inc.'s net income of -$20.2M is lower than Neogen Corp.'s net income of -$15.9M. Notably, Outlook Therapeutics, Inc.'s price-to-earnings ratio is -- while Neogen Corp.'s PE ratio is 2,124.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics, Inc. is 10.52x versus 2.28x for Neogen Corp.. Usually stocks with elevated PS ratios are considered overvalued.